Treatment with 300 mg IV eptinezumab in adults with chronic migraine resulted in rapid and sustained reduction in the number of headache days that was largely sustained up to 84 weeks, according to a ...

Patients with migraine discontinued treatment less often with atogepant and experienced a greater reduction in mean monthly ...